Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2189265 versus Metformin in Early Type 2 Diabetes Mellitus
2009-014841-10Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in HbA1c at 26 weeks. Started Feb 2010; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-014841-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014841-10.